Dubbed "Sherlock," the new technology has demonstrated potential in detecting viruses and bacteria as well as human SNPs and mutations in cell-free DNA.
Facing CMS sanctions, lab industry insiders ponder the firm's options in seeking to launch a Zika virus assay with emergency use authorization on its upcoming miniLab platform.
At the American Association for Clinical Chemistry meeting, Theranos CEO Elizabeth Holmes said her company is working on third-party review and publications of the firm's technologies and tests.
Researchers led by MIT's Jim Collins have built upon their paper-based Ebola test and are hoping to find a partner to help scale production and manufacturing of the test.
The company plans to add assays for Group B Streptococcus, Clostridium difficile, and norovirus in 2016 to complement its existing meningitis test.
The test is the first in the Dublin, Ireland-based firm's pipeline of infectious disease assays that use loop-mediated isothermal amplification.
Lumora's MDx technology for the clinical and industrial sectors will be merged with ERBA Mannheim's IVD testing business in a wide range of market segments.
The 3M Molecular Detection Assay 2 – Listeria monocytogenes is 30 percent faster than the first-generation test.
Meridian's Diagnostics segment grew 2 percent lifted by a 10 percent increase in revenues from the illumigene molecular product line.
The assay is the first on the firm's isothermal nucleic acid amplification-based platform.
Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.
The New York Times reports that a number of companies and research institutes are pursuing gene therapies.
Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.
In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.